Unknown

Dataset Information

0

PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy.


ABSTRACT: Gastrointestinal (GI) malignancies are the most prevalent tumors worldwide, with increasing incidence and mortality. Although surgical resection, chemotherapy, radiotherapy, and molecular targeted therapy have led to significant advances in the treatment of GI cancer patients, overall survival is still low. Therefore, alternative strategies must be identified to improve patient outcomes. In the tumor microenvironment, tumor cells can escape the host immune response through the interaction of PD-1 and PD-L, which inhibits the function of T cells and tumor-infiltrating lymphocytes while increasing the function of immunosuppressive T regulatory cells. The use of an anti-PD-1/PD-L blockade enables reprogramming of the immune system to efficiently identify and kill tumor cells. In recent years, the efficacy of PD-1/PD-L blockade has been demonstrated in many tumors, and this treatment is expected to be a pan-immunotherapy for tumors. Here, we review the signaling pathway underlying the dysregulation of PD-1/PD-L in tumors, summarize the current clinical data for PD-1/PD-L inhibitors in GI malignancies, and discuss road toward precision immunotherapy in relation to PD-1/PD-L blockade. The preliminary data for PD-1/PD-L inhibitors are encouraging, and the precision immunotherapy of PD-1/PD-L inhibitors will be a viable and pivotal clinical strategy for GI cancer therapy.

SUBMITTER: Long J 

PROVIDER: S-EPMC5543600 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy.

Long Junyu J   Lin Jianzhen J   Wang Anqiang A   Wu Liangcai L   Zheng Yongchang Y   Yang Xiaobo X   Wan Xueshuai X   Xu Haifeng H   Chen Shuguang S   Zhao Haitao H  

Journal of hematology & oncology 20170803 1


Gastrointestinal (GI) malignancies are the most prevalent tumors worldwide, with increasing incidence and mortality. Although surgical resection, chemotherapy, radiotherapy, and molecular targeted therapy have led to significant advances in the treatment of GI cancer patients, overall survival is still low. Therefore, alternative strategies must be identified to improve patient outcomes. In the tumor microenvironment, tumor cells can escape the host immune response through the interaction of PD-  ...[more]

Similar Datasets

| S-EPMC6891823 | biostudies-literature
| S-EPMC6389077 | biostudies-literature
| S-EPMC6036392 | biostudies-literature
| S-EPMC4485757 | biostudies-literature
| S-EPMC6942585 | biostudies-literature
| S-EPMC5506270 | biostudies-literature
| S-EPMC5512095 | biostudies-literature
| S-EPMC5956851 | biostudies-literature
| S-EPMC6771592 | biostudies-literature
| S-EPMC8136112 | biostudies-literature